Download PDF
Thromb Haemost 2021; 121(02): 224-233
DOI: 10.1055/s-0040-1715834
Stroke, Systemic or Venous Thromboembolism

Direct Oral Anticoagulant Concentrations in Obese and High Body Weight Patients: A Cohort Study

Anne Céline Martin
1   Department of Cardiology, European Hospital Georges Pompidou, Paris, France
2   University of Paris, Innovative Therapies in Haemostasis, INSERM UMRS1140, Paris, France
,
William Thomas
3   Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
,
Zahra Mahir
4   Department of Haematology, Thrombosis & Haemophilia Centre, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom
,
Maeve P. Crowley
5   Department of Haematology, Cork University Hospital, Cork, Ireland
,
Terry Dowling
6   Rushbottom Lane Surgery, Benfleet, Essex, United Kingdom
,
Karen Breen
4   Department of Haematology, Thrombosis & Haemophilia Centre, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom
,
Victoria Collings
4   Department of Haematology, Thrombosis & Haemophilia Centre, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom
,
Gary W. Moore
7   Diagnostic Haemostasis and Thrombosis, Viapath, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom
,
Stephen MacDonald
3   Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
,
Beverley J. Hunt
4   Department of Haematology, Thrombosis & Haemophilia Centre, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom
,
Alexander T. Cohen
4   Department of Haematology, Thrombosis & Haemophilia Centre, Guy's and St Thomas' Hospitals NHS Foundation Trust, London, United Kingdom
› Author Affiliations Funding None declared.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Background Direct oral anticoagulants (DOACs) are prescribed for atrial fibrillation (AF) and venous thromboembolism (VTE) and both occur more frequently in obese patients. Outcomes from DOAC trials included few individuals ≥ 120 kg leading to uncertainty whether high body weight (BW) reduces DOAC concentrations.

Objectives This article investigates the relationship between factor Xa (FXa) inhibitor concentrations, BW, and renal function, and compares them in high BW patients with unselected populations.

Methods Consecutive patients in two United Kingdom centers, weighing ≥ 120 kg receiving 5 mg twice daily apixaban or 20 mg once daily rivaroxaban for AF or VTE were prospectively included. Peak or trough concentrations were measured using specific chromogenic assays, expressed in mean or median (5th–95th percentiles). On-therapy range was the interval from the 5th percentile trough concentration to the 95th percentile peak concentration.

Results One hundred patients were included; age range: 23 to 78 years, 31% were women, 58% had AF, creatinine clearance range: 67 to 474 mL/min. Median BW was 139 kg, and 84% had body mass index (BMI) ≥ 40 kg/m2. DOAC peak and trough concentrations varied from 44 to 727 and 14 to 299 ng/mL, respectively. There was no linear relationship between FXa inhibitor concentrations at peak or trough and BW or BMI, and creatinine clearance. Apixaban troughs in AF and rivaroxaban peaks in VTE were lower than in unselected populations. However, only two trough concentrations were below the expected range, and 109/116 were within the on-therapy range.

Conclusion These data indicated that obese or high BW patients generally achieve therapeutic FXa inhibitor concentrations. However, further investigations assessing clinical outcomes are required.

Keywords

direct oral anticoagulants - high body weight and obesity - atrial fibrillation - venous thromboembolism - drug concentrations

Authors' Contributions

A.-C.M. designed and performed research, analyzed data, and wrote the manuscript. W.T. designed and performed the research and wrote the manuscript. Z.M. performed research and reviewed and revised the manuscript. M.P.C. performed research and reviewed and revised the manuscript. T.D. performed research and reviewed and revised the manuscript. K.B. performed research and reviewed and revised the manuscript. V.C. performed research and reviewed and revised the manuscript. G.W.M. and S.M.D. coordinated the sample swap and ran the samples for the analysis. G.W.M. and S.M.D. also appraised the manuscript while it was being written and provided feedback and approval. B.H. performed research and reviewed and revised the manuscript. A.T.C. designed and performed the research, analyzed the data, and wrote the manuscript. All authors performed the research, contributed to the manuscript, reviewed the manuscript while it was being written, provided feedback, and gave final approval.




Publication History

Received: 19 June 2020

Accepted: 21 July 2020

Article published online:
30 August 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

Letter to this article:

Direct Oral Anticoagulant Dosing in Extremes of Body Weight: Time to Revisit the Guidelines?Thromb Haemost 2021; 121(02): 118-120
DOI: 10.1055/s-0040-1716753

 

  • References

  • 1 Konstantinides SV, Meyer G, Becattini C. et al; ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41 (04) 543-603
    CrossrefPubMedSearch in Google Scholar
  • 2 Kirchhof P, Benussi S, Kotecha D. et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
    CrossrefPubMedSearch in Google Scholar
  • 3 Cuker A. Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication. J Thromb Thrombolysis 2016; 41 (02) 241-247
    CrossrefPubMedSearch in Google Scholar
  • 4 Severinsen MT, Kristensen SR, Johnsen SP, Dethlefsen C, Tjønneland A, Overvad K. Anthropometry, body fat, and venous thromboembolism: a Danish follow-up study. Circulation 2009; 120 (19) 1850-1857
    CrossrefPubMedSearch in Google Scholar
  • 5 Wang TF, Carrier M. How I treat obese patients with oral anticoagulants. Blood 2020; 135 (12) 904-911
    CrossrefPubMedSearch in Google Scholar
  • 6 Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14 (06) 1308-1313
    CrossrefPubMedSearch in Google Scholar
  • 7 Speed V, Green B, Roberts LN. et al. Fixed dose rivaroxaban can be used in extremes of bodyweight: a population pharmacokinetic analysis. J Thromb Haemost 2020; 18 (09) 2296-2307
    CrossrefPubMedSearch in Google Scholar
  • 8 Rocca B, Fox KAA, Ajjan RA. et al. Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. Eur Heart J 2018; 39 (19) 1672-1686f
    CrossrefPubMedSearch in Google Scholar
  • 9 Gosselin RC, Adcock DM, Bates SM. et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 2018; 118 (03) 437-450
    Thieme ConnectPubMedSearch in Google Scholar
  • 10 Bhagirath VC, Eikelboom JW, Hirsh J. et al. Apixaban-calibrated anti-FXa activity in relation to outcome events and clinical characteristics in patients with atrial fibrillation: results from the AVERROES trial. TH Open 2017; 1 (02) e139-e145
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Ruff CT, Giugliano RP, Braunwald E. et al. Association between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015; 385 (9984): 2288-2295
    CrossrefPubMedSearch in Google Scholar
  • 12 Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007; 47 (02) 218-226
    CrossrefPubMedSearch in Google Scholar
  • 13 Upreti VV, Wang J, Barrett YC. et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol 2013; 76 (06) 908-916
    CrossrefPubMedSearch in Google Scholar
  • 14 Giugliano RP, Ruff CT, Braunwald E. et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
    CrossrefPubMedSearch in Google Scholar
  • 15 Piran S, Traquair H, Chan N, Bhagirath V, Schulman S. Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: a retrospective study. Res Pract Thromb Haemost 2018; 2 (04) 684-688
    CrossrefPubMedSearch in Google Scholar
  • 16 Arachchillage D, Reynolds R, Devey T, Maclean R, Kitchen S, van Veen JJ. Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience. Thromb Res 2016; 147: 32-35
    CrossrefPubMedSearch in Google Scholar
  • 17 Wasan SM, Feland N, Grant R, Aston CE. Validation of apixaban anti-factor Xa assay and impact of body weight. Thromb Res 2019; 182: 51-55
    CrossrefPubMedSearch in Google Scholar
  • 18 Testa S, Paoletti O, Legnani C. et al. Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost 2018; 16 (05) 842-848
    CrossrefPubMedSearch in Google Scholar
  • 19 Patel MR, Mahaffey KW, Garg J. et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
    CrossrefPubMedSearch in Google Scholar
  • 20 Hohnloser SH, Fudim M, Alexander JH. et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight. Circulation 2019; 139 (20) 2292-2300
    CrossrefPubMedSearch in Google Scholar
  • 21 Di Nisio M, Vedovati MC, Riera-Mestre A. et al. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies. Thromb Haemost 2016; 116 (04) 739-746
    Thieme ConnectPubMedSearch in Google Scholar
  • 22 Peterson ED, Ashton V, Chen YW, Wu B, Spyropoulos AC. Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation. Am Heart J 2019; 212: 113-119
    CrossrefPubMedSearch in Google Scholar
  • 23 Deitelzweig S, Keshishian A, Kang A. et al. Effectiveness and safety of oral anticoagulants among NVAF patients with obesity: insights from the ARISTOPHANES study. J Clin Med 2020; 9 (06) E1633
    CrossrefPubMedSearch in Google Scholar
  • 24 Costa OS, Beyer-Westendorf J, Ashton V. et al. Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data. Curr Med Res Opin 2020; 36 (07) 1081-1088
    CrossrefPubMedSearch in Google Scholar
  • 25 van Es N, Coppens M, Schulman S, Middeldorp S, Büller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; 124 (12) 1968-1975
    CrossrefPubMedSearch in Google Scholar
  • 26 Kushnir M, Choi Y, Eisenberg R. et al. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Lancet Haematol 2019; 6 (07) e359-e365
    CrossrefPubMedSearch in Google Scholar